Anika Therapeutics, Inc. Form 4 August 03, 2015 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 MB Number: 3235-0287											
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may cont <i>See</i> Instr 1(b).	ger 5 66. 5 5 5 5 5 5 5 5 5 5 5 5 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(h) of the Investment Company Act of 1940								Expires:January 31, 2005Estimated average burden hours per response0.5	
(Print or Type l	Responses)										
1. Name and A LAND RAY	2. Issuer Name <b>and</b> Ticker or Trading Symbol Anika Therapeutics, Inc. [ANIK]					5. Relationship of Reporting Person(s) to Issuer					
(Last)	(First) (M	Aiddle) 3.	3. Date of Earliest Transaction (Check					k all applicable)			
			(Month/Day/Year) 07/30/2015					X_ Director10% Owner Officer (give title Other (specify below) below)			
				. If Amendment, Date Original iled(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City)							-	uired, Disposed of		•	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution D any (Month/Day)	ate, if	Code (Instr. 3, 4 and 5) ear) (Instr. 8) (A)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	07/30/2015			S	690	D	\$ 37.39	14,499	D		
Common Stock (1)	07/30/2015			М	1,540	А	\$ 12.36	16,039	D		
Common Stock	07/30/2015			F	522 <u>(2)</u>	D	\$ 36.51	15,517	D		
Common Stock	07/31/2015			S	1,018	D	\$ 37.76	14,499	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SE information contained in this form are not

SEC 1474 (9-02)

#### Edgar Filing: Anika Therapeutics, Inc. - Form 4

# required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

D S	. Title of verivative ecurity instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					Code V	' (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
A	tock Appreciation Light	\$ 12.36	07/30/2015		М		1,540	<u>(1)</u>	12/14/2016	Common Stock	1,540

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1 8	Director	10% Owner	Officer	Other			
LAND RAYMOND J 32 WIGGINS AVENUE BEDFORD, MA 01730	Х						
Signatures							
/s/ Charles H. Sherwood, Attorney-in-fact	08/03/2015						

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise of stock appreciation rights ("SARs") granted on December 14, 2006 vesting in four annual installments beginning December 14, 2007.
- (2) Reflects 522 shares of common stock utilized to cover the exercise of the above listed SARs awards by the Reporting Person on July 30, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.